National Cancer Institute (NCI) is recruiting patients for a PHASE2 clinical trial testing HIPEC (heated intraperitoneal chemotherapy) for mesothelioma.
The trial, designated NCT05001880, aims to enroll up to 66 participants at 39 sites, including locations in Arizona, Illinois, Kentucky.
About the Study
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Treatment Approach
This trial uses heated chemotherapy delivered directly into the abdominal cavity during surgery.
Key trial details:
- Phase: PHASE2
- Sponsor: National Cancer Institute (NCI)
- Enrollment target: 66
- Status: RECRUITING
Why This Trial Matters
HIPEC has shown promise for peritoneal mesothelioma, with some patients achieving long-term survival when combined with cytoreductive surgery. This trial is sponsored by the National Cancer Institute, signaling significant federal investment in mesothelioma research.
Study Locations
The trial is recruiting at:
- Mayo Clinic Hospital in Arizona, Arizona
- University of Chicago Comprehensive Cancer Center, Illinois
- Carle at The Riverfront, Illinois
- Carle Physician Group-Effingham, Illinois
- Carle Physician Group-Mattoon/Charleston, Illinois
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening